The impact of androgen‐deprivation therapy ( <scp>ADT</scp> ) on the risk of cardiovascular ( <scp>CV</scp> ) events in patients with non‐metastatic prostate cancer: a population‐based study

Abstract

The administration of GnRH agonists, but not orchidectomy, is still associated with a significantly increased risk of CAD, AMI, and, especially, SCD in patients with non-metastatic prostate cancer. Alternative forms of ADT should be considered in patients at higher risk of CV events.